Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R.H. Brown, E.A. Zerhouni, W. Mitzner.
Variability in the size of individual airways over the course of one year.
Am J Respir Crit Care Med, 51 (1995), pp. 1159-1164
[2.]
J. Hruby, J. Butler.
Variabiliy of routine pulmonary function tests.
Thorax, 30 (1975), pp. 548-553
[3.]
A. Dawson.
Reproducibility of spirometric measurements in normal subjects.
Am Rev Respir Dis, 93 (1966), pp. 264-268
[4.]
C.J. Herold, R.H. Brown, W. Mitzner, J.M. Links, C.A. Hirsman, E.A. Zerhouni.
High resolution computed tomography: a new method to asses pulmonary airway reactivity.
Radiology, 181 (1991), pp. 374-396
[5.]
R.H. Brown, C.J. Herold, C.A. Hirsman, E.A. Zerhouni, W. Mitzner.
In vivo measurement of airway rectivity using high-resolution computed tomography.
Am Rev Respir Dis, 144 (1991), pp. 208-212
[6.]
S.A. Wood, E.A. Zerhouni, J.D. Hoford, E.A. Hoffman, W. Mitzner.
Measurement of three-dimensional lung tree y using computed tomography.
J Appl Physiol, 79 (1995), pp. 1687-1697
[7.]
C.J. Rozas, A.L. Goldman.
Daily spirometric variability: normal subjets and subjets with chronic bronchitis with and without airflow obstruction.
Arch Intern Med, 142 (1982), pp. 1287-1291
[8.]
B.G. Nickereson, R.J. Lemen, C.B. Gerdes, M.J. Wegmann, G. Rodertson.
Within-subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis.
Am Rev Respir Dis, 122 (1980), pp. 859-866
[9.]
A. Nagai, I. Yamawaki, T. Takizawa, W.M. Thurlbeck.
Alveolar attachments in emphysema of human lungs.
Am Rev Respir Dis, 144 (1991), pp. 888-891
[10.]
J. Wright, L. Cagle, A. Churg, T.V. Colby, J. Myers.
Diseases of the small airways.
Am Rev Respir Dis, 146 (1992), pp. 240-262
[11.]
N.R. Anthonisen, E.C. Wright, y el IPPB Trial Group.
Bronchodilator response in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 133 (1986), pp. 814-819
[12.]
Committee on emphysema American College of Chest Physicians.
Criteria for the assessment of reversibility in airways obstruction.
Chest, 65 (1974), pp. 552-553
[13.]
G.L. Snider, C.R. Woolf, R.C. Kory, J. Ross.
Criteria for the assessment of reversibility in air-ways obstruction. Report of the Committee on Emphysema: American College of Chest Physicians.
Chest, 65 (1974), pp. 552-553
[14.]
A. Ries.
Response to bronchodilators.
Pulmonary function testing guideliness and controversies, Orlando. Game? Stration, pp. 215-221
[15.]
SEPAR.
Normativa para la práctica de la espirometría forzada.
Arch Bronconeumol, 25 (1989), pp. 132-142
[16.]
J.E. Cotes.
Lung function.
4.ª, Blackwell Scientific, (1979),
[17.]
American Thoracic Society.
Lung function testing: selection of reference values and interpretative strategies.
Am Rev Respir Dis, 144 (1991), pp. 1202-1218
[18.]
Ph.H. Quanjer, G.S. Tammeling, J.E. Cotes, O.F. Pedersen, R. Peslin, J.C. Yennault.
Lung volumes and forced ventilatory flows, Resport working party standardization of lung function tests. European Community for steel and coal.
Eur Respir J, 6 (1993), pp. 5-40
[19.]
ATS., Statement.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. 77-120
[20.]
N.M. Siafakas, P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, P. Howard, on behalf of the Task Force, et al.
ERS Consensus Statement, Optimal assessment and management of chronic obstructive pulmonary disease (COPD).
Eur Respir J, 8 (1995), pp. 1398-1420
[21.]
A. Díez Herranz, M. Tobal González.
La interpretación de la espirometría: ¿dónde nos encontramos?.
Arch Bronconeumol, 32 (1996), pp. 475-482
[22.]
Harf, A..
How to express the reversibility of bronchial obstruction?.
Eur Respir J, 5 (1992), pp. 919-920
[23.]
O. Selroos, Pietinalho, H. Riska.
Delivery devices for inhaled asthma medication - Clinical implications of differences in effectiveness.
Clin Immunotherapy, 54 (1986), pp. 287-288
[24.]
M.D. Short, C.A. Singh, J.D. Few, P.R. Studdy, P.J.D. Heaf, S.G. Spiro.
The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent.
Chest, 80 (1981), pp. 918-921
[25.]
S.P. Newman, A.W.B. Weisz, N. Talaee.
Clark. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique.
Thorax, 46 (1991), pp. 712-716
[26.]
B.N. Zamuidin, M. Biddiscombe, S.E.J. Tolfree, M. Short, S.G. Spiro.
Comparison of bronchodilatador response and deposition patterns of salbutamol inhaladed from a pressurised aerosol metered dose inhaler, as a dry powder and as a nebulised solution.
Thorax, 45 (1993), pp. 469-473
[27.]
L. Borgstrom, E. Bondesson, F. Moren, E. Trofast, S.P. Newman.
Lung deposition of budesonide inhaled via turbuhaler: a comparison with terbutaline in normal subjets.
Eur Respir J, 7 (1994), pp. 69-73
[28.]
S.P. Newman, A.B. Nillar, Lennard-Jones, F. Moren, S.W. Clarke.
Improvement of pressurized aerosol deposition with Nebuhaler spacer device.
Thorax, 39 (1984), pp. 935-941
[29.]
R. Melchor, M.F. Biddiscombe, V.H.F. Mak, M.D. Shooort, S.G. Spiro.
Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.
Thorax, 48 (1993), pp. 506-511
[30.]
P.A. Corris, E. Neville, S. Nariman, G.J. Gibson.
Dose-response study of inhaled salbutamol powder in chronic airflow obstruction.
Thorax, 38 (1983), pp. 292-296
[31.]
J. Britton, A. Tatterfield.
Comparison of cumulative and non-cumulative techniques to mesure dose-response curves for betaagonists in patients with asthma.
Thorax, 39 (1984), pp. 579-599
[33.]
D.S. Potsma, K.D. Vries, G.H. Koeter, H.J. Sluiter.
Independent influence of reversibility of airflow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic airflow obstruction.
Am Rev Respir Dis, 134 (1986), pp. 276-280
[34.]
D.P. Tashkin, K. Ashutosh, E.R. Bleecker, E.J. Birtt, D.W. Cugell, J.M. Cummiskey, et al.
Comparison of the anticholinergic bronchodilator ipratropium bromide with metaporterrenol in chronic obstructive pulmonary disease. A 90 day multi-centre study.
Am J Med, 81 (1986), pp. 81-90
[35.]
M. Mayos, M. González, P. Casán, J. García-Barbal, J. Sanchís.
Comparación entre procaterol y salbutamol mediante dosis-respuesta acumulada en pacientes con limitación crónica al flujo aéreo.
Arch Bronconeumol, 25 (1989), pp. 65-68
[36.]
M. Nisar, M. Walshaw, J.E. Earis, M.G. Pearson, P.M. Calverly.
Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.
Thorax, 45 (1990), pp. 190-194
[37.]
H.A.M. Kerstjens, P.L.P. Brand, P.H. Quanjer, B.A.H.A. Van deer Bruggen- Bogaarts, G.H. Koëter, D.S. Postma, on behalf of the Dutch CNSLD Study Group.
Variability of bronchodilator response and effects of inhalad corticosteroid treatment in obstructive airways disease.
Thorax, 48 (1993), pp. 722-729
[38.]
M. Nisar, J.E. Earis, M.G. Pearson, P.M.A. Calverly.
Acute bronchodilator trials in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 146 (1992), pp. 555-559
[39.]
S.R. Braun, W.N. Mckenzie, C. Copeland, L. Knight, M. Ellersieck.
A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease.
Arch Intern Med, 149 (1989), pp. 544-547
[40.]
D.M. Newnham, D.P. Dhillon, J.H. Winter, C.M. Jackson, R.A. Clark, B.J. Lipworth.
Brochodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.
Thorax, 48 (1993), pp. 1151-1155
[41.]
S.C. Jenkins, J. Moxham.
High dose salbutmol in chronic bronchitis: comparison of 400 mg, 1 mg, 1.6 mg, 2 mg and placebo delivered by rotahalar.
Br J Dis Chest, 81 (1987), pp. 242-247
[42.]
B.J. Lipworth, R.A. Clark, D.P. Dhillon, D.G. McDevitt.
Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoeptor responsiveness in patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis, 142 (1990), pp. 338-342
[43.]
L. Gómez, M. Rodríguez-Carballeira, S. Quintana, L. Esteban, C. Viñas, J.L. Heredia.
The bronchodilator response with increasing dose of terbutalina.
Eur Respir J, 7 (1994), pp. S330
[44.]
M. Rodríguez-Carballeira.
Prueba broncodilatadora en pacientes con enfermedad pulmonar obstructiva crónica [Tesis doctoral], Universidad Autónoma de Barcelona, (1999),
[45.]
R. Jaesckie, G.H. Guyatt, D. Cook, J. Morris, A. Willan, W. McIlroy, et al.
The effect of increasing doses of β-agonist on airflow in patients with chronic airflow limitation.
Respir Med, 87 (1993), pp. 433-438
[46.]
L.E. Klock, T.D. Miller, A.H. Morris, S. Watanabe, M. Dickman.
A comparative study of atropine sulfate and isoproterol hydrochloride in chronic bronchitis.
Am Rev Respir Dis, 112 (1975), pp. 371-376
[47.]
K. Ashutosh, G. Dev, D. Steele.
Non bronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease.
Chest, 107 (1995), pp. 173-178
[48.]
A. Ikeda, K. Nishimura, H. Koyama, T. Izumi.
Comparative doseresponse study of three antichollinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.
Thorax, 50 (1993), pp. 62
[49.]
G. Wesseling, R. Mostert, E.F.M. Wouters.
A comparison of the effects of anticholinergic and beta-2-agonist and combination therapy on respiratory impedance in COPD.
Chest, 101 (1992), pp. 166-173
[50.]
P. Lloberas, L. Ramis, J.M. Montserrat, J. Serra, J. Campistol, C. Picado, A. Agustí-Vidal.
Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease.
Eur Respir J, 1 (1988), pp. 536-539
[51.]
S.R. Braun, S.F. Levy, J. Grossman.
Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study.
Am J Med, 91 (1991), pp. 28-32
[52.]
E. Imhof, S. Elsasser, W. Karrer, M. Grossenbacher, R. Emmons, A.P. Perruchoud.
Comparison of bronchodilator effect of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease.
Respiration, 60 (1993), pp. 84-88
[53.]
G.R. Petrie, K.N.V. Palmer.
Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma.
Br Med J, 1 (1975), pp. 430-432
[54.]
N.J. Douglas, I. Davidson, M.F. Sudlow, D.C. Flenley.
Bronchodilation and the site of airway resistance in severe chronic bronchitis.
Thorax, 34 (1979), pp. 51-56
[55.]
J.A. Hughes, M.J. Tobin, D. Bellamy, D.C.S. Hutchison.
Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema.
Thorax, 37 (1982), pp. 667-670
[56.]
M. Rodríguez-Carballeira, J.L. Heredia, L. Gómez, S. Quintana, C. Viñas.
Contribution of Ipratropium Bromide of the bronchodilator test in patients with chronic obstructive pulmonary disease.
Pulmon Pharmacol Ther, 12 (1999), pp. 43-48
[57.]
M. Rodríguez-Carballeira, M. Rué, S. Quintana, L. Gómez, J.L. Heredia.
Bronchodilator test with terbutaline and ipratropium bromide in patients with COPD.
Eur Respir J, 10 (1997), pp. 37
[58.]
J.J. Marini, S. Lakshminarayan.
The effect of atropine inhalation in “irreversible” chronic bronchitis.
Chest, 77 (1980), pp. 591-596
[59.]
P.M. Passamonte, A.J. Martínez.
Effect of inhaled atropine or metaproterenol in patients with chronic airway obstruction and therapeutic serum theophylline levels.
Chest, 85 (1984), pp. 610-615
[60.]
S.A. Quadrelli, A.J. Roncoroni, G. Porcel.
Analysis of variability in interpretation of spirometric tests.
Respiration, 63 (1996), pp. 131-136
[61.]
R.W. Light, S.A. Conrad, R.B. George.
Clinical significance of pulmonary function tests. The one best test for evaluating the effects of bronchodilator therapy.
Chest, 72 (1977), pp. 512-516
[62.]
B.E. Pennock, R.M. Rogers, D.R. McCaffree.
Changes in measured spirometric indices. What is significant?.
Chest, 80 (1981), pp. 97-99
[63.]
R. Berger, D. Smith.
Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction.
Chest, 93 (1988), pp. 541-546
[64.]
M.J. Barrons, P.J. Rees.
Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction.
Respir Med, 84 (1990), pp. 311-315
[65.]
M.S. Noah, M.M. Kabiraj, A.K. Abdullah, A.U. Zaman.
Measurement of reversibility of airways obstruction: which parameters to use?.
Respiration, 48 (1985), pp. 24-28
[66.]
P.M. Tweeddale, F. Alexandeer, G.J.R. McHardy.
Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.
Thorax, 42 (1987), pp. 487-490
[67.]
J.W. Ramsdell, G.M. Tisi.
Determination of bronchodilation in the clinical pulmonary function laboratory.
Chest, 76 (1979), pp. 622-628
[68.]
C.A. Kelly, G.J. Gibson.
Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction.
Thorax, 43 (1988), pp. 335-336
[69.]
F.W. Dekker, A.C. Schrier, P.J. Sterk, J.H. Dijkman.
Validity of peak expiratory flow measurement in assessing of airway obstruction.
Thorax, 47 (1992), pp. 162-166
[70.]
B. Armitage, G. Berry.
Statistical methods for research workers.
3.ª, Blackwell Scientific Publications, (1994),
[71.]
S.M. Ayres, S.J. Griesbach, F. Reilmond, R.G. Evans.
Bronchial component in chronic obstructive lung disease.
Am J Med, 57 (1974), pp. 183-191
[72.]
T.R. Baker, M. Oscherwitz, R. Corlin, E. Jarboe, J. Teisch, M.Z. Nichaman.
Screening and treatment program for mild chronic obstructive pulmonary disease.
JAMA, 214 (1970), pp. 1448-1455
[73.]
L. Prieto, R. Lamarca, A. Casado.
La evaluación de la fiabilidad en las observaciones clínicas: el coeficiente de correlación intraclase.
Med Clin (Barc), 110 (1998), pp. 142-145
[74.]
R. Mora Ripoll, C. Ascaso Terrén, J. Sentís Vialta.
Uso actual de la estadística en investigación biomédica: una comparación entre revistas de medicina general.
Med Clin (Barc), 106 (1996), pp. 451-456
[75.]
R. Mora Ripoll, C. Ascaso Terrén, J. Sentís Vialta.
Tendencias actuales en la utilización de la estadística en medicina Estudio de los artículos publicados en Medicina Clínica (1991-1992).
Med Clin (Barc), 104 (1995), pp. 444-447
[76.]
G.H. Guyatt, M. Townsend, S. Nogradi, S. Pugsley, J. Keller, M.T. Newhouse.
Acute response to bronchodilator.
Arch Intern Med, 148 (1988), pp. 1949-1952
[77.]
R. Gabriel Sánchez, C. Villasante Fernández-Montes, J.M. Pino García, F. García Río, M. Miravitlles, C.A. Jiménez Ruiz, et al.
Estimación de la variabilidad inicial interobservador de la espirometría forzada en el estudio epidemiológico multicéntrico IBERCOP.
Arch Bronconeumol, 33 (1997), pp. 300-305
[78.]
S. Chinn, J.R. Britton, P.G.J. Burney, A.E. Tattersfield, A.O. Papacosta.
Estimation and repeatibility of the response to inhaled histamine in a community survey.
Thorax, 42 (1987), pp. 45-52
[79.]
N. Meslier, J.L. Racinaux.
Test of reversibility of airway obstruction.
Eur Respir Rev, 1 (1991), pp. 34-40
[80.]
P.L. Brand, P.H. Quanjer, D.S. Postma, H.A.M. Kerstjens, G.H. Koëter, P.N.R. Dekhuijzen, H.J. Sluiter, y el Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.
Interpretation of bronchodilator response in patients with obstructive airways disease.
Thorax, 47 (1992), pp. 429-436
[81.]
N. Meslier, J.L. Racineux, P. Six, A. Lockhart.
Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach.
Eur Respir J, 2 (1989), pp. 497-505
[82.]
D.C. Weir, P.S. Burge.
Measures of reversibility in response to bronchodilators in chronic airflow obstruction: relation to airway calibre.
Thorax, 46 (1991), pp. 43-45
[83.]
P. Gayrard, J. Orehek.
Mesure d’un effet bronchodilateur par le VEMS: comment l’exprimer?.
Rev Mail Respir, 1 (1984), pp. 81-84
[84.]
M. Demedts.
The assessment of reversibility: what physiological tests?.
Eur Respir J, 3 (1990), pp. 1084-1087
[85.]
E. Dompeling, C.P. Van Schayck, J. Molema, R. Akkermans, H. Folgering, P.M. Van Grusnven, et al.
A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.
Eur Respir J, 5 (1992), pp. 975-981
[86.]
D.S. Postma, F. Gimeno, L.T.H.V.D. Weele, H.J. Sluiter.
Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility.
Eur J Respir Dis, 67 (1985), pp. 360-368
[87.]
M.R. Miller, A.C. Pincock.
Predicted values: how should we use them?.
Thorax, 43 (1988), pp. 265-267
[89.]
R.E. Dales, W.O. Spitzer, P. Tousignant, M. Schechter.
Clinical interpretation of airway response to a bronchodilator.
Epidemiologic considerations. Am Rev Respir Dis, 138 (1988), pp. 317-320
[90.]
N.R. Anthonisen, E.C. Wright, e IPPB Trial Groups.
Response to inhaled bronchodilators in COPD.
Chest, 915 (1987), pp. 36-39
[91.]
M.W. Pratter, R.S. Irwin.
Predicting response to bronchodilator therapy in chronic obstructive pulmonary disease.
Arch Intern Med, 148 (1988), pp. 1909-1910
[92.]
L. Gómez, M. Rodríguez-Carballeira, S. Quintana, L. Esteban, C. Viñas, J.L. Heredia.
Espirometrías repetidas en pacientes con enfermedad pulmonar obstructiva crónica: variabilidad de la prueba broncodilatadora.
Arch Bronconeumol, 30 (1994), pp. 152-153
[93.]
O. Eliasson, A.C. Degraff.
The use of criteria for reversibility and obstruction to define patients groups for bronchodilator trials.
Am Rev Respir Dis, 132 (1985), pp. 858-864
[94.]
G.T. Ferguson, R.M. Cherniack.
Management of chronic obstructive pulmonary disease.
N Engl J Med, 328 (1993), pp. 1017-1022
[95.]
G.H. Guyatt, M. Townsend, S. Nogradi, S.O. Pugsley, J.L. Keller, M.T. Newhouse.
Acute response to bronchodilator.
Arch Intern Med, 148 (1988), pp. 1949-1952
[96.]
M. Rodríguez-Carballeira, L. Gómez, S. Quintana, M. Rue, L. Esteban, C. Viñas, et al.
Estudio de broncorreversibilidad en pacientes con EPOC severa.
Arch Bronconeumol, 32 (1996), pp. 8
[97.]
W.L. Dull, M.R. Alexander, P. Sadoul, R.F. Woolson.
The efficacy of isoproterenol inhalation for predicting the response to orally administered theophylline in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 126 (1982), pp. 656-659
[98.]
D.A. Mahler, D.H. Weinberg, C.K. Wells, A.R. Feinstein.
The measurement of dyspnea.
Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest, 85 (1984), pp. 751-758
[99.]
D.A. Mahler, R.A. Rosiello, A. Harver, T. Lentine, J.F. McGovern, J.A. Daubenspeck.
Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease.
Am Rev Respir Dis, 135 (1987), pp. 1229-1233
[100.]
D.A. Mahler, R.A. Matthay, P.E. Snyder, C.K. Wells, J. Loke.
Sutained- release theophylline reduces dyspnea in nonreversible obstructive airway disease.
Am Rev Respir Dis, 131 (1985), pp. 22-25
[101.]
M.L. Eaton, F.M. MacDonald, T.R. Church, D.E. Niewoehner.
Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction.
Chest, 82 (1982), pp. 538-542
[102.]
J.L. Heredia, M. Rodríguez, S. Quintana, I. Mir, C. Viñas, L. Gómez.
Percepción de mejoría en el asma.
Med Clin (Barc), 105 (1995), pp. 612-614
[103.]
P.W. Jones.
Issues concerning health-related quality of life in COPD.
Chest, 107 (1995), pp. 187-193
[104.]
A. Noseda, J. Schmerber, T. Prigogine, J.C. Yernault.
How do patients with either asthma or COPD perceive acute bronchodilation?.
Eur Respir J, 6 (1993), pp. 636-644
[105.]
D.B. Lorber, W. Kaltenborn, B. Burrows.
Responses to isoproterenol in a general pupulation sample.
Am Rev Respir Dis, 118 (1978), pp. 855-861
[106.]
H.A. Boushey, M.J. Holtzman, J.R. Sheller, J.A. Nadel.
Bronchial Hyperreactivity.
Am Rev Respir Dis, 121 (1980), pp. 389-413
[107.]
B. Burrows, R.H. Earle.
Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients.
N Engl J Med, 280 (1969), pp. 397-404
[108.]
G.A. Traver, M.G. Cline, B. Burrows.
Predictors of mortality in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 119 (1979), pp. 895-902
[109.]
D.S. Postma, H.J. Sluitter.
Predictors of mortality in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 121 (1980), pp. 1056-1057
[110.]
D.S. Postma, J. Burema, F. Gimeno, J.F. May, J.M. Smit, E.J. Steenhuis, et al.
Prognosis in severe chronic obstructive pulmonary disease.
Am Rev Respir Dis, 119 (1979), pp. 357-367
[111.]
C.E. Barter, A.H. Campbell, M.K. Tandon.
Factors affecting the decline of FEV1 in chronic bronchitis.
Aust NZ J Med, 4 (1974), pp. 339-345
[112.]
C.E. Barter, A.H. Campbell.
Relationship of constitutional factors and cigarette smoling to decrease in 1-second forced expiratory volume.
Am Rev Respir Dis, 113 (1976), pp. 305-314
[113.]
W.M. Vollmer, L.R. Johnson, A.S. Buist.
Relationship of response to a bronchodilator and decline in forced expiratory volume in one second in population studies.
Am Rev Respir Dis, 132 (1985), pp. 1186-1193
[114.]
C. Pellicer Ciscar, M. Perpiñá Tordera, A. De Diego Damiá, V. Macián Gisbert.
Aportación del test broncodilatador al estudio de la reversibilidad bronquial.
Arch Bronconeumol, 30 (1994), pp. 492-497
[115.]
S. Kesten, A.S. Rebuck.
Is the shot-term response to inhaled β adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?.
Chest, 105 (1994), pp. 1042-1045
[116.]
A. Minette.
Spirometric study of the bronchodilation effects of hydroxyphenylorciprenaline (Th 1165 a) in various forms in a group of 124 coal miners suffering from bronchospasm.
Respiration, 27 (1970), pp. 276-315
[117.]
A.S. Vathenen, J.R. Britton, P. Ebben, J.B. Cookson, H.J. Wharrad, A.E. Tattersfield.
High-dose inhaled albuterol in severe chronic airflow limitation.
Am Rev Respir Dis, 138 (1988), pp. 850-855
[118.]
P.J. Barnes, S. Pedersen, W.W. Busse.
Supplement: efficacy and safety of inhaled corticosteroids: news developments.
Am J Respir Crit Care Med, 157 (1998), pp. S1-S59
[119.]
P.S. Burge.
EUROSCOP, ISOLDE and the Copenhagen City Lung Study.
Thorax, 54 (1999), pp. 287-288
[120.]
P.L. Paggiaro, R. Dahle, I. Bakran, L. Frith, F. Hollingworth, J. Efhimiou, on behalf of the International COPD Study Group.
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
Lancet, 351 (1998), pp. 773-780
[121.]
P.M. Van Grusven, C.P. Van Schayck, J.P. Derenne, H.A. Kerstjens, T.E.J. Renkema, D.S. Postma, et al.
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a metaanalysis.
Thorax, 54 (1999), pp. 7-14
[122.]
R.A. Pawles, C.G. Löfdahl, L.A. Laininen, J.P. Schouten, D.S. Postma, N.B. Pride, et al.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive disease who continue smoking.
N Engl J Med, 340 (1999), pp. 1948-1953
[123.]
S.M. Harding, S.A. Freedman.
A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response.
Thorax, 33 (1978), pp. 214-218
[124.]
L.A. Mendella, J. Manfreda, C.P.W. Warren, N.R. Anthonisen.
Steroids response in stable chronic obstructive pulmonary disease.
Ann Intern Med, 96 (1982), pp. 17-21
[125.]
P. Weiner, M. Weiner, Y. Azgad, D. Damir.
Inhaled budesonide therapy for patients with stable COPD.
Chest, 109 (1995), pp. 1568-1571
[126.]
C.P. Van Schayck, P.M. Van Grusven, P.N.R. Dekhuijzen.
Do patients with COPD benefit from treatment with inhaled corticosteroidea?.
Eur Respir J, 9 (1996), pp. 1969-1972
[127.]
H.A. Kerstjens, S.E. Overbeek, J.P. Shouten, P.L. Brand, D.S. Postma, and the Duch CNSLD Study Group.
Airways hyperresponsiveness, bronchodilatador response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment.
Eur Respir J, 6 (1993), pp. 868-876
[128.]
E. Dompeling, C.P. Van Schayck, P.M. Van Grunsven, C.L.A. Van Herwaarden, R. Akkermans, J. Molema, et al.
Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhlaed corticosteroids. A 4-year prospective study.
Ann Intern Med, 118 (1993), pp. 770-778
[129.]
H.A. Kerstjens, P.L. Brand, M.D. Hughes, N.J. Robinson, D.S. Postma, H.J. Sluiter, and the Dutch Chronic Non-Specific Lung Disease Study Group, et al.
A comparison of bronchodilator therapy for obstructive airways disease.
N Engl J Med, 327 (1992), pp. 1413-1419
[130.]
M.P. Rutten-Van Mölken, E.K. Van Doorslaer, M.C. Jansen, H.A. Kerstjens, F.F. Rutten.
Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 151 (1995), pp. 975-982
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica
